TY - JOUR
T1 - Interferon-α Therapy and Anti-Human Leukocyte Antigen Antibodies in Hepatitis C Virus-Positive Patient
T2 - Case Report
AU - Cervelli, C.
AU - Fontecchio, G.
AU - Fioroni, M. A.
AU - Azzarone, R.
AU - Battistoni, C.
AU - Maccarone, D.
AU - Pisani, F.
AU - Papola, F.
PY - 2007/7
Y1 - 2007/7
N2 - Interferon-alpha (IFN-α) is currently the only treatment for patients with chronic hepatitis C. Yet it can induce acute renal transplantation rejection possibly by stimulating humoral responses. We tested patient sera for detection of donor-specific anti-human leukocyte antigen (HLA) antibodies observing an increased panel-reactive antibodies value after IFN-α therapy. Then, we also investigated whether antiviral treatment with IFN-α was related to an increased and/or different production of class I and class II anti-HLA antibodies. Patient sera analysis performed by a cytofluorimetric method using flow PRA tests showed the appearance of new HLA-antibody specificities. This study underlined that INF-α therapy modifies a patient's immune profile; hence, it is recommended to confirm HLA-antibody specificities after treatment in order to protect recipients from enhanced rejection risk owing to a false-negative donor-specific cross-match.
AB - Interferon-alpha (IFN-α) is currently the only treatment for patients with chronic hepatitis C. Yet it can induce acute renal transplantation rejection possibly by stimulating humoral responses. We tested patient sera for detection of donor-specific anti-human leukocyte antigen (HLA) antibodies observing an increased panel-reactive antibodies value after IFN-α therapy. Then, we also investigated whether antiviral treatment with IFN-α was related to an increased and/or different production of class I and class II anti-HLA antibodies. Patient sera analysis performed by a cytofluorimetric method using flow PRA tests showed the appearance of new HLA-antibody specificities. This study underlined that INF-α therapy modifies a patient's immune profile; hence, it is recommended to confirm HLA-antibody specificities after treatment in order to protect recipients from enhanced rejection risk owing to a false-negative donor-specific cross-match.
UR - http://www.scopus.com/inward/record.url?scp=34547568876&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547568876&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2007.05.013
DO - 10.1016/j.transproceed.2007.05.013
M3 - Article
C2 - 17692687
AN - SCOPUS:34547568876
VL - 39
SP - 2040
EP - 2041
JO - Transplantation Proceedings
JF - Transplantation Proceedings
SN - 0041-1345
IS - 6
ER -